Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07788404

Population Pharmacokinetic Model of Rifampicin in Staphylococcal Osteoarticular Infections

Staphylococcal osteoarticular infections (OAIs), including prosthetic joint infections and chronic osteomyelitis, represent a major cause of morbidity. Rifampicin is a key bactericidal antibiotic effective against staphylococcal biofilm. However, its pharmacokinetics exhibit substantial inter-individual variability due to complex hepatic metabolism and drug interactions. Currently, no prospective population pharmacokinetic (PopPK) model of rifampicin combined with levofloxacin or ciprofloxacin exists in patients with OAIs. Objectives:

The primary objective of this study is to develop a population pharmacokinetic model of oral rifampicin in patients undergoing medico-surgical treatment for staphylococcal osteoarticular infections. Secondary objectives include evaluating the pharmacokinetics of the partner antibiotic (levofloxacin or ciprofloxacin), investigating the correlation between antibiotic exposure metrics (AUC, Cmax, AUC/MIC) and clinical/biological tolerance, and assessing 1-year infection relapse-free survival and resistance emergence. Study Design:

Prospective, single-center, interventional study with minimal risks and constraints (RIPH 2) involving 40 participants recruited at the Reference Center for Complex Osteoarticular Infections (CRIOAC).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Prosthetic Joint Infection Bacterial Infections Bacterial Infections and Mycoses Bone Diseases Bone Diseases, Infectious Gram-Positive Bacterial Infections Infections Musculoskeletal Diseases Osteomyelitis Staphylococcal Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Groupe hospitalier Diaconesses Croix Saint Simon

Paris, 75020, France

Location status: Recruiting

Location contact

Valerie ZELLER, Infectious disease specialist

PRINCIPAL_INVESTIGATOR

Younes KERROUMI, Clinical Research Physician

CONTACT

[email protected]

0033144643384

About this study

Study Workflow and Pharmacokinetic Sampling Protocol:

Screening and Baseline: Adult patients hospitalized for staphylococcal prosthetic joint infection, chronic osteomyelitis, or native joint infection sensitive to rifampicin and levofloxacin/ciprofloxacin are screened. Clinical, demographic (age, sex, actual and ideal body weight), and biological data (renal function, liver function, serum albumin) are collected.

Pharmacokinetic Blood Sampling (12 samples total, 60 mL total volume): Day 2 / Day 3: 5 blood samples (5 mL each) collected pre-dose (t0, fasting) and at 1h, 2h, 4h, and 8h post-dose of rifampicin. Day 8 / Day 10: 5 blood samples (5 mL each) collected pre-dose (t0, fasting) and at 1h, 2h, 4h, and 8h post-dose of rifampicin and partner antibiotic (levofloxacin or ciprofloxacin). Day 28 / Day 32 (1-month follow-up visit): 2 blood samples (5 mL each) collected pre-dose and 2 hours post-dose during outpatient consultation.

Pharmacokinetic and Statistical Modeling: Population PK parameters (CL/F, V/F, ka) and inter-individual variability will be estimated using non-linear mixed-effects modeling (NONMEM v7.5). Influence of covariates (age, sex, weight, renal function, serum albumin) will be evaluated. One-Year Follow-up: Clinical follow-up at 12 months post-treatment initiation to evaluate infection relapse, tolerance, and microbiological

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient informed about the study and signed written consent obtained
  • Male or female participant aged 18 years or older
  • Staphylococcal osteoarticular infection (prosthetic joint infection of hip, knee, or shoulder; chronic osteomyelitis; or native joint infection) susceptible to rifampicin and levofloxacin or ciprofloxacin
  • Indication for combined medico-surgical treatment of the osteoarticular infection

Exclusion criteria

  • Septic shock requiring vasopressor support
  • Prior rifampicin treatment within 1 month preceding inclusion
  • Contraindication to rifampicin (known allergy, major drug interaction, or hepatic cirrhosis)
  • End-stage renal disease on chronic dialysis
  • Pregnant or breastfeeding woman
  • Adult patient unable or unfit to give informed consent
  • Subject deprived of liberty by judicial or administrative decision
  • Subject not affiliated with or beneficiary of a national social security scheme

Treatment and study plan

This study focuses on the pharmacokinetics of rifampicin and levofloxacin or ciprofloxacin, which are used in the treatment of osteoarticular infections caused by susceptible staphylococci as part of

Drug

This study primarily aims to evaluate the pharmacokinetics of rifampicin, but also of one of the two partner antibiotics, levofloxacin or ciprofloxacin, used in the treatment of staphylococcal osteoarticular infections, whether or not they are present in the body. To this end, 12 blood samples, totaling 60 ml per patient, will be required. These samples will be collected specifically for this clinical research. The remainder of the study will be conducted as part of standard patient care.

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve (AUC) of Rifampicin

    Time frame: Day 2/3, Day 8/10, and Day 28/32 post-initiation of antibiotic therapy

    Area under the plasma concentration-time curve of oral rifampicin, estimated using a population pharmacokinetic non-linear mixed-effects model (NONMEM).

  2. Peak Plasma Concentration (Cmax) of Rifampicin

    Time frame: Day 2/3, Day 8/10, and Day 28/32 post-initiation of antibiotic therapy

    Maximum observed plasma concentration (Cmax) of oral rifampicin, measured following administration.

  3. Apparent Oral Clearance (CL/F) of Rifampicin

    Time frame: Through 4 weeks post-initiation of antibiotic therapy

    Apparent oral clearance (CL/F) of rifampicin estimated using a population pharmacokinetic model (NONMEM), including evaluation of inter-individual variability and covariate effects.

  4. Apparent Volume of Distribution (V/F) of Rifampicin

    Time frame: Through 4 weeks post-initiation of antibiotic therapy

    Apparent volume of distribution (V/F) of rifampicin estimated using a population pharmacokinetic model (NONMEM), including evaluation of inter-individual variability and covariate effects.

Secondary outcomes

  1. Incidence of Clinical and Biological Adverse Events Related to Rifampicin Exposure

    Time frame: Through 4 weeks post-initiation of antibiotic therapy

    Proportion of patients experiencing clinical or biological adverse events (recorded in CRF) evaluated in relation to rifampicin Cmax and AUC.

  2. Infection Relapse-Free Survival at 1 Year Relative to Rifampicin AUC/MIC Ratio

    Time frame: 12 months post-initiation of antibiotic therapy

    Time to staphylococcal infection relapse over a 1-year follow-up period, analyzed in relation to the rifampicin AUC/MIC (Minimum Inhibitory Concentration) ratio.

  3. Emergence of Rifampicin Resistance at Relapse

    Time frame: 12 months post-initiation of antibiotic therapy

    Assessment of rifampicin MIC (determined by E-test) at the time of infection relapse compared to baseline, evaluated according to Cmax/MIC and AUC/MIC ratios.

  4. Peak Plasma Concentration (Cmax) of Partner Antibiotic

    Time frame: Day 8/10 and Day 28/32 post-initiation of antibiotic therapy

    Maximum observed plasma concentration (Cmax) of the partner antibiotic (levofloxacin or ciprofloxacin) administered in combination with rifampicin.

  5. Trough Plasma Concentration (Cmin) of Partner Antibiotic

    Time frame: Day 8/10 and Day 28/32 post-initiation of antibiotic therapy

    Trough plasma concentration (Cmin) of the partner antibiotic (levofloxacin or ciprofloxacin) measured prior to the next scheduled dose.

  6. Apparent Clearance (CL/F) of Partner Antibiotic

    Time frame: Day 8/10 and Day 28/32 post-initiation of antibiotic therapy

    Apparent clearance (CL/F) of the partner antibiotic (levofloxacin or ciprofloxacin) administered in combination with rifampicin.

  7. Area Under the Plasma Concentration-Time Curve (AUC) of Partner Antibiotic

    Time frame: Day 8/10 and Day 28/32 post-initiation of antibiotic therapy

    Area under the plasma concentration-time curve (AUC) of the partner antibiotic (levofloxacin or ciprofloxacin) administered in combination with rifampicin.

Sponsors and collaborators

Lead sponsor

Groupe Hospitalier Diaconesses Croix Saint-Simon

Other

Registry information

Acronym: Ciné-RIF

Important dates

Study start
2023
Primary completion
2028
Study completion
2029
First posted
Aug 26, 2026
Registry last updated
Aug 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.